Find trials
Consejos para buscar

Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species

Overview

Información sobre este estudio

The purpose of this study is to obtain and report outcome data for adult subjects who received systemic antifungal therapy (AFT) for the treatment of invasive mucormycosis (IM) or invasive aspergillosis (IA) caused by a non-fumigatus species.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  1. Subject has proven or probable IM or IA caused by a non-fumigatus species per EORTC/MSG criteria. Subjects with multiple fungal pathogens are eligible (i.e., niger/fumigatus, Rhizopus/Absidia).
  2. Subject is 18 years of age at the time they began treatment with a systemic AFT for their IFI.
  3. Subject has received or is receiving treatment with a systemic AFT active against IM or IA caused by a non-fumigatus species.
  4. Subject initiated systemic AFT for treatment of IM or IA caused by a non-fumigatus species in January 2016 or later.
  5. Subject or legal representative has provided the appropriate consent and/or release, consistent with local requirements, to access medical records given consent and/or data release if required by institutional policy, state and/or governmental laws, including access to all relevant clinical and medication data, and the storage and analysis of this data.
  6. Subject who has completed therapy prior to registration must have day 42 vital status data available.

Exclusion Criteria:

  1. Subject only underwent surgery for the treatment of IM or IA caused by a non-fumigatus species (i.e., subject did not receive systemic antifungal treatment).
  2. Subject previously provided data for this registry.
  3. Subject who received an investigational drug used to treat an IFI within 30 days of starting treatment with an approved antifungal for their IFI.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Robert Orenstein, D.O.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20343322

Mayo Clinic Footer